Business model to the rescue, not emerging markets
This article was originally published in Scrip
Three unconnected news stories have caught the attention of most pharma industry radars this week. On the surface, they have nothing to do with each other. Catching attention are: India’s Biocon and Pfizer terminating a biosimilar insulin alliance; Bayer losing exclusivity on cancer drug Nexavar (sorafenib tosylate) in India, which has invoked its first ever compulsory licence; and AstraZeneca’s legal fight with the FDA to extend US patent life for the blockbuster antipsychotic Seroquel (quetiapine fumarate).